SAN FRANCISCO, July 12, 2018 /PRNewswire/ --
The global assisted reproductive technology (ART)
market is expected to reach USD 45
billion by 2025, according to a new report by Grand View
Research, Inc. Childbearing postponement is one of the high impact
rendering drivers of the infertility treatment market. The
reproductive behavior and pattern of some of the nations such as
few European nations have shifted from early to late childbearing
pattern.
(Logo:
https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg
)
Increasing marital age, rising tobacco and alcohol consumption,
increasing obesity rate are some of the other factors contributing
to the market growth. Furthermore, increasing incidence rate of
conditions such as poly-cystic ovarian syndrome (PCOS), tubal
factors and endometriosis are other drivers of the market.
According to the Society for Assisted Reproductive Technology,
2012 was the year with highest percentage of babies born through
IVF treatment. The treatment has become more successful and has
gained more acceptance, which is further expected to increase the
market size in the coming years.
Browse full research report with TOC on
"Assisted Reproductive Technology (ART) Market Size,
Share & Trends Analysis Report By Type (IVF, AI-IUI, FER,
Others), By End Use (Hospitals, Fertility Clinics), By Procedures
And Segment Forecasts, 2018 - 2025" at:
https://www.grandviewresearch.com/industry-analysis/assisted-reproductive-technology-market
Further Key Findings From the Report Suggest:
- Fresh non-donor was the largest ART market procedure segment in
2014. The fact that fresh eggs and sperms increase the number of
successful pregnancies is expected to drive segment growth over the
forecast period.
- According to a recent study published in the New England
Journal of Medicine.by the researchers from Vietnam and China, frozen embryos are not more effective
in comparison to the fresh embryos for all women, specifically
those suffering from PCOS.
- Frozen non-donor is identified as the most lucrative procedure
segment of the assisted reproductive technology industry. A new
study claims that the fertility treatment with frozen embryos may
have more probability of success than those performed with fresh
embryos.
- IVF with ICSI dominated the technology type market segment
owing to increase in the chances of successful fertilization, and
exceptional technique for treating male infertility. As per the
study published in fertility journal Human Reproduction Update
2017, North America, Europe, New
Zealand and Australia,
men's sperm counts declined by 50-60% over the period between 1973
and 2011. Changing lifestyle and environmental factors are some of
the factors responsible for the decline of sperm counts.
- Frozen embryo replacement (FER) is anticipated to grow at a
rapid rate over the forecast period owing to the fact that in the
clinics fresh embryos are used first and only good quality and
spare embryos are transferred at a later stage. The trend is to
transfer single embryos rather than risking by transferring two or
more embryos. This is expected to increase the FER segment market
in the coming years.
- Europe dominated the market
and is anticipated to maintain its dominance during the forecast
period The Asia Pacific region is
likely to witness significant growth over the next decade due to
improving healthcare infrastructure, increasing awareness and
adoption of IVF procedures.
- Technological advancements is expected to drive the market in
the coming years. In 2016, INVO Bioscience, Inc. announced the FDA
approval of first intravaginal culture system, INVOcell, wherein
women's vagina is used as a natural incubator and the clinical
trials have produced pregnancy similar to traditional IVF
treatments
- Some of the key players are California Cryobank, Bloom IVF
Centre, Parallabs, OvaScience, Anecova, Origio, Microm Ltd., Merck
KGaA, Ferring Pharmaceuticals, Boston Science Corporation and
Hamilton Throne Ltd.
Browse related reports by Grand View Research:
- Proteomics Market - The global proteomics market was
valued at over USD 11.8 billion in
2015.
- Next Generation Sequencing (NGS) Data Analysis Market
- The Global Next Generation Sequencing (NGS) data analysis
market was valued at USD 459.1
million in 2015.
- Biochip Market - The Global biochip market was
valued at USD 7.63 billion in 2015
and comprehensive drug development pipeline is expected to drive
growth in revenue
- Therapeutic Drug Monitoring Market - The global
therapeutic drug monitoring market was valued USD 1.77 billion in 2015.
Grand View Research has segmented the global assisted
reproductive technology market based on procedure, type, end use
and region:
- Procedure Outlook (Revenue, USD
Million, 2014 - 2025)
- Fresh Donor
- Fresh Non-Donor
- Frozen Donor
- Frozen Non-donor
- Embryo/Egg Banking
- Type Outlook(Revenue, USD Million, 2014 - 2025)
- In-Vitro Fertilization (IVF)
- IVF with Intracytoplasmic Sperm Injection (ICSI)
- IVF without Intracytoplasmic Sperm Injection (ICSI)
- AI-IUI (Artificial Insemination - Intrauterine
Insemination
- Frozen Embryo Replacement (FER)
- Others
- End Use Outlook (Revenue, USD Million, 2014 -
2025)
- Hospitals
- Fertility Clinics
- Regional Outlook (Revenue, USD Million, 2014 -
2025)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Explore the BI enabled intuitive market research
database, The Grand Library, by Grand View Research,
Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company
provides syndicated research reports, customized research reports,
and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant
and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
SOURCE Grand View Research, Inc.